Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
KEAPSAKE trial: what clinicians have said so far
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
- NCT04265534 ↗
- Terminated
- Calithera Biosciences, Inc
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on KEAPSAKE (telaglenastat in first-line metastatic KEAP1/NRF2-mutated nonsquamous NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEAPSAKE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung; KEAP1 Gene Mutation; NRF2 Gene Mutation; NFE2L2 Gene Mutation
- Interventions
- Telaglenastat; Carboplatin Chemotherapy; Pemetrexed Chemotherapy; Pembrolizumab Immunotherapy; Placebo; Folic acid 400 -1000 μg; Vitamin B12 1000 μg; Dexamethasone 4 mg
- Arms
- Telaglenastat with Pembrolizumab and Chemotherapy · Experimental
- Placebo with Pembrolizumab and Chemotherapy · Placebo comparator
- Enrollment
- 40
- Primary outcomes
- Progression-Free Survival (PFS), Assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Safety and Tolerability of Telaglenastat Plus Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Type, Incidence, Severity, Seriousness, and Study Drug Relatedness of Adverse Events per CTCAE v5.0
- Recommended Phase 2 Dose of Telaglenastat in Combination with Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Incidence and Nature of Protocol Defined Dose-Limiting Toxicities (DLTs) During the Safety Run-in Period
- Sponsor
- Calithera Biosciences, Inc
- Start
- Jul 24, 2020
- Primary completion
- Nov 5, 2021
- Results posted
- No
- Registry record
- NCT04265534 · updated Sep 21, 2022
Publications
linked from the registry- Aden D, Sureka N, Zaheer S, Chaurasia JK, Zaheer S. Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment. Immunology. 2025 Jan;174(1):30-72. doi: 10.1111/imm.13871. Epub 2024 Oct 27. PubMed 39462179